Health Canada updates safety information on Lamictal (lamotrigine)

August 5, 2011

Health Canada Endorsed Important Safety Information on LAMICTAL (lamotrigine): Important Safety Information Concerning Interactions of the Anti-epileptic Drug Lamictal

In September 2004, GlaxoSmithKline Inc. distributed a letter to Canadian healthcare professionals concerning the safety of the anti-epileptic drug, Lamictal. Women who combined Lamictal with their birth control pills  have reported the following:

  • seizures
  • unexpected pregnancies
  • menstrual bleeding disorders (e.g. breakthrough bleeding)

Health Canada advised women to inform their doctors if they are taking birth control pills or other female hormonal treatments (e.g. hormone replacement therapy). Patients should never start or stop their medication without consulting a physician first.

Click here to see Health Canada’s complete the advisory page

Leave a Reply

Your email address will not be published. Required fields are marked *